ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Delivery

Mantra raises $25 million for exosome-based drug delivery

by Ryan Cross
August 13, 2020 | APPEARED IN VOLUME 98, ISSUE 31

Mantra Bio, a San Francisco–based start-up quietly founded in 2016, has raised $25 million in series A financing to develop exosome-based therapies. Exosomes are lipid vesicles, released from cells, that usually contain RNA or proteins. Mantra is one of a number of start-ups looking to hijack exosomes for drug delivery. The firm specializes in discovering and engineering exosomes that can target specific cells or tissues in the body.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment